Antimalarials Arrhythmias, Cardiac COVID-19 Chemoprevention Editorial Humans Hydroxychloroquine Randomized Controlled Trials as Topic Risk Assessment SARS-CoV-2 United States adverse event antimalarial agent chemoprophylaxis comorbidity coronavirus disease 2019 disease severity drug efficacy drug safety drug therapy heart arrhythmia hospital discharge hospital patient human hydroxychloroquine infection prevention infection risk length of stay mortality outcome assessment